MDMA therapy for PTSD and opioid addiction after childbirth
Part of Mental health clinical trials.
This Phase 2 study tests whether MDMA-assisted therapy can reduce symptoms of PTSD and help with opioid use disorder in people after childbirth. You must be on a stable, low enough dose of methadone or buprenorphine and be able to follow study rules, including therapy sessions and safety monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have opioid use disorder and have been stable for at least 3 months on a daily methadone dose of 180 mg or less or buprenorphine dose of 24 mg or less.
- Your PTSD is moderate to severe, started at least 6 months ago, and has been at least moderate in the past month.
- You can speak and read English, and you can swallow pills.
- You agree to have study visits recorded and to safety check-ins (including informing the team about new medical issues within 48 hours).
- If you could become pregnant: you must be not pregnant at entry and use effective birth control during the study and after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a therapy called prolonged exposure (a type of talk therapy) delivered via video calls to help people with both opioid use disorder and PTSD. It aims to see if this approach can reduce PTSD symptoms.
This study tests whether psilocybin (a compound found in certain mushrooms), given with therapy, can help people with moderate to severe opioid use disorder reduce their opioid use. Participants must have stable housing and a support person to join.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
This study tests a postpartum intervention for mothers diagnosed with opioid use disorder (or receiving opioid addiction treatment) to help during the period after having a baby. You may be eligible if you have a young child and can complete the study tasks, including possible questionnaires and an MRI if needed.
This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.